NEW YORK (GenomeWeb News) – Hologic provided an update on its pending $3.7 billion acquisition of Gen-Probe after the close of the market on Wednesday, saying the deal is expected to be completed on or about Aug. 1.

In addition, its said that Carl Hull, chairman and CEO of Gen-Probe, has agreed to stay on at Hologic for at least 15 months to help direct the combined company's diagnostics business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.